Mark D. Tyson II, MD, MPH, discusses findings from the phse 3b PATAPSCO study, evaluating durvalumab plus BCG for patients with BCG-naïve, high-risk NMIBC. PATAPSCO was designed as a US-based ...
FDA Breakthrough Device Designation was granted to an AI-powered H&E-based prognostic assay for bladder cancer, described as the first such designation in this disease setting. Proprietary foundation ...
“The overall survival showed a 25% reduction in the risk of death. This is statistically significant,” said Thomas B. Powles, MBBS, MRCP, MD. Results of a large phase 3 study support the use of ...
In May 2024, the FDA cleared an investigational new drug application for 225Ac-FL-020. The FDA has awarded a fast track designation to 225 Ac-FL-020, an investigational PSMA-targeting radionuclide ...
In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.
EMBARK enrolled 1068 men with high-risk BCR post-local therapy, conventional-imaging M0 status, PSA ≥1 ng/mL post-prostatectomy or ≥2 ng/mL above post-EBRT nadir, and PSADT ≤9 months. A protocolized ...
Chad A. Reichard, MD, highlights real-world data presented at AUA 2026 on re-induction with nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer. In an ...
Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC. The novel hybrid design used in the phase 2 ARASEC trial (NCT05059236) 1 —and ...
TLX250-CDx aims to address unmet needs in ccRCC imaging, with a potential U.S. commercial launch in 2025. The FDA's initial concerns were related to sterility assurance, not the agent's safety or ...
The FDA approved neoadjuvant durvalumab with gemcitabine and cisplatin, followed by adjuvant durvalumab, for muscle invasive bladder cancer (MIBC). Phase 3 NIAGARA trial results showed improved ...
A 500 mg dose of abiraterone acetate showed comparable efficacy to the standard 1000 mg dose in prostate cancer treatment, with a favorable safety profile. The study demonstrated significant PSA ...
ARASEC provides US-based, contemporary evidence supporting darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, demonstrating a 71% reduction in prostate cancer-specific mortality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results